How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC
L Chen, X Jiang, Y Li, Q Zhang, Q Li, X Zhang… - Clinical …, 2022 - Elsevier
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death-1/anti-
programmed cell death ligand-1 (anti-PD-1/PD-L1) therapy, have elicited impressive clinical …
programmed cell death ligand-1 (anti-PD-1/PD-L1) therapy, have elicited impressive clinical …
How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.
L Chen, X Jiang, Y Li, Q Zhang, Q Li… - Clinical Immunology …, 2022 - europepmc.org
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death-1/anti-
programmed cell death ligand-1 (anti-PD-1/PD-L1) therapy, have elicited impressive clinical …
programmed cell death ligand-1 (anti-PD-1/PD-L1) therapy, have elicited impressive clinical …
How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC
L Chen, X Jiang, Y Li, Q Zhang, Q Li… - Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death-1/anti-
programmed cell death ligand-1 (anti-PD-1/PD-L1) therapy, have elicited impressive clinical …
programmed cell death ligand-1 (anti-PD-1/PD-L1) therapy, have elicited impressive clinical …